DiagnosTear

What DiagnosTear does

DiagnosTear Technologies Inc. (CSE:DTR; Frankfurt-listed) is an Israel-based, clinical-to-commercial-stage ophthalmic diagnostics company developing the TeaRx™ platform, a point-of-care system that performs multi-parameter analysis of tear fluid for eye disease diagnosis and monitoring. The platform is built around a proprietary single-use microfluidic tear collector that captures approximately one microliter of tear fluid with a color-change sampling indicator, followed by a semi-quantitative multi-parameter immunoassay and a cloud-based interpretive readout; the full procedure is reported to take under ten minutes. The first cleared product, TeaRx Dry Eye, holds CE-IVD and Israeli Ministry of Health (AMAR) approvals and is offered in 3-parameter and 5-parameter versions, with company-reported clinical performance of 86% sensitivity and 87% specificity for high-severity disease and ≥94% prediction of Cyclosporine A treatment responsiveness validated in a 600-subject study. A pipeline product, TeaRx Red Eye, is positioned as a first-of-its-kind differential test for adenoviral conjunctivitis, Herpetic Keratitis and allergic conjunctivitis, with manufacturing tooling for 100,000 units completed in early 2025 and clinical studies underway in France (AlyaTec), India (LV Prasad Eye Institute) and Israel.

The company sells diagnostic devices and consumable tear collectors to healthcare providers — primarily ophthalmologists for dry eye management and primary care physicians (GPs, family practitioners, pediatricians) for red eye differential diagnosis — with additional targeting of pharmaceutical companies and CROs (e.g., Lexitas Pharma Services) for use in ophthalmic clinical trials as a patient stratification and treatment-response biomarker. The revenue model is device-plus-consumable (single-use tear collectors) sold B2B, which the company describes as one-time per test/device sale with recurring consumable pull-through potential. Go-to-market is a hybrid of direct enterprise sales and regional channel partnerships, illustrated by the February 2026 Letter of Intent with UK-based Hanson Medical for UK distribution and engagement of bullVestor Medien GmbH for European marketing. The company became public in February 2024 via a Reverse Takeover transaction and commenced CSE trading in December 2024, subsequently listing on the Frankfurt Stock Exchange in October 2025.

Name

DiagnosTear

Legal name

DiagnosTear Technologies Inc.

Website

http://www.diagnostear.com

Company type

Public

Founded year

2013

Operating status

Operating

Headcount range

1–10 employees

Short description

DiagnosTear Technologies Inc. develops and commercializes the TeaRx point-of-care tear-fluid diagnostic platform for ophthalmic disease, serving ophthalmologists, primary care physicians and ophthalmic clinical trials with CE-IVD-cleared dry eye and red eye tests.

Ownership category

akta.pro rank

Product category

Ophthalmic Diagnostics

NAICS

Electromedical and Electrotherapeutic Apparatus Manufacturing (334510)

SIC

Surgical & Medical Instruments & Apparatus (3841), In Vitro & In Vivo Diagnostic Substances (2835)

akta.pro primary industry

Dry Eye & Ocular Surface Devices (Meibography, Tear Osmolarity, IPL, Thermal Pulsation) (HLAHAJAF)

Keywords

• Ophthalmic diagnostics
• Tear fluid analysis
• Point-of-care testing
• Dry eye diagnosis
• Microfluidic immunoassay

Headquarters

HQ city

Tel Aviv

HQ country

Israel

HQ region

Middle East

Offices1 record

Markets served

GTM type

B2B

Offering type

Hardware or Manufacturing

Cost components

Technology or R&D, Personnel, Operations, Marketing or Sales, Others

Revenue model

1. Diagnostic Device Sales: DiagnosTear generates revenue through the sale of its TeaRx diagnostic devices and proprietary tear collectors. The company sells point-of-care diagnostic tests for dry eye syndrome and red eye conditions. Revenue is one-time per test/device sale, with potential for recurring purchases as the tear collector is single-use.

Go-to-market motion2 records

Distribution channels1 record

Marketing channels8 records

Core offering

DiagnosTear develops and commercializes the TeaRx™ point-of-care diagnostic platform that analyzes tear fluid to identify, monitor, and stratify ophthalmic conditions such as Dry Eye Syndrome and red eye pathologies. The platform combines a proprietary single-use microfluidic tear collector with a multi-parameter immunoassay and cloud-based algorithm interpretation, delivering results in under 10 minutes for use by ophthalmologists and primary care physicians.

Product overview

DiagnosTear offers the TeaRx™ platform as its core diagnostic technology. The platform consists of TeaRx™ Dry Eye (CE-IVD approved test for identification and monitoring of Dry Eye Syndrome), TeaRx™ Red Eye (differential diagnosis of adenoviral conjunctivitis, Herpetic Keratitis, and Allergic conjunctivitis), and the TeaRx™ Tear Collector (proprietary microfluidic tear collection device). The TeaRx platform uses tear fluid analysis with multi-parameter immunoassays and cloud-based algorithmic interpretation, with the whole procedure taking less than 10 minutes.

Differentiator

Problem solved

Functional benefit

Brands

• TeaRx: Diagnostic platform for point-of-care testing of ophthalmic pathologies through multi-parameter composition analysis of tear fluid, including TeaRx Dry Eye and TeaRx Red Eye products.

Products and services

• TeaRx Dry Eye The first CE-IVD approved point-of-care test based on the TeaRx platform, intended for the identification and monitoring of Dry Eye Syndrome (DES). Available in 3-parameter and 5-parameter versions, with clinical trials demonstrating 86% sensitivity and 87% specificity for detection of high severity DES, ≥80% sensitivity for differentiating severe vs. non-severe Dry Eye, and ≥94% prediction of Cyclosporine A responsiveness at baseline. Targeted at ophthalmologists and eye-care specialists.
• TeaRx Red Eye The first test of its kind for differential assessment of adenoviral conjunctivitis, Herpetic Keratitis, and allergic conjunctivitis using tear fluid analysis. Designed for use by primary care physicians, family practitioners, pediatricians, and ophthalmologists to enable on-site differentiation of viral vs. allergic red eye without requiring referral. Clinical trials are underway in India (LV Prasad Eye Institute), France (AlyaTec), and with Sun Pharma and Israel's largest HMO.
• TeaRx Tear Collector DiagnosTear's proprietary single-use microfluidic tear collector that is an integral part of the TeaRx technology. Allows simple, non-invasive collection of 1 microliter of tear fluid and subsequent dilution in assay buffer, with proper sampling ensured by a color change (from brown to yellow) on the tip of the micro-capillary. Offered as a standalone consumable component.

Quantifiable outcome

• 86% sensitivity and 87% specificity for detection of high severity Dry Eye Syndrome
• +4 more outcomes

Segments3 records

Ideal customer profiles3 records

Technology focussed Yes

API detail

Has API

No

API docs

API detail

Core technology

AI maturity

App detail

Feature5 records

Partnerships

Six partnerships are on record, tiered core and minor.

• AlyaTeccoreStrategic or Co-development Partner · 26 February 2026Clinical study collaboration with French CRO AlyaTec following regulatory and ethics approvals from French authorities (ANSM and the French Ethics Committee). The study evaluates total tear IgE as a biomarker for Allergic Conjunctivitis using the TeaRx™ Red Eye diagnostic platform. Patient recruitment and sampling have commenced to finalize analytical validation supporting the FDA submission pathway.
• Hanson MedicalcoreChannel Partner/ Reseller/ Distributor · 20 February 2026Non-binding Letter of Intent to explore commercial partnership for the TeaRx™ dry-eye diagnostic platform in the United Kingdom under a defined period until May 15, 2026. During the LOI period, Hanson Medical conducts market evaluation activities and engages with eye-care professionals to assess clinical integration and commercial adoption pathways. The initiative is part of DiagnosTear's strategy to build localized partnerships in key European markets and may lead to a definitive commercial agreement.
• Lexitas Pharma Services, Inc.coreStrategic or Co-development Partner · 13 September 2023Partnership for the use of TeaRx™ in ophthalmic clinical trials. Lexitas Pharma Services provides clinical research services and incorporates TeaRx tear-based diagnostics for patient stratification and treatment response measurement in clinical studies.
• LV Prasad Eye InstitutecoreStrategic or Co-development PartnerClinical trials partnership for TeaRx Red Eye development conducted in partnership with LV Prasad Eye Institute in India. LV Prasad Eye Institute is a leading eye care institution providing research collaboration for clinical validation of tear-based diagnostic tests.
• Sun PharmaminorStrategic or Co-development PartnerPartnership mentioned for TeaRx Red Eye development alongside other clinical collaborations. Sun Pharma is a pharmaceutical company involved in ophthalmic treatments.
• Israel's Largest Health Maintenance OrganizationminorStrategic or Co-development PartnerClinical trial partnership for TeaRx Red Eye with Israel's largest Health Maintenance Organization for tear-based diagnostic development.

Scale indicators8 records

Recent moves9 records

Expansion highlights6 records

Market position

Competitive moat3 records

Key highlights7 records

Customer concentration

• Xx.com/DiagnosTear
• LinkedInlinkedin.com/company/diagnostear

Compliance3 records

Revenue estimate

Valuation estimate

Number of profiles

Profiles13 records

Funding overview

Funding rounds1 record

Investors

Funding detail is available on the Subscription and Enterprise plan.Contact sales →

M&A

Investments

M&A and investment is available on the Subscription and Enterprise plan.Contact sales →

Frequently asked questions about DiagnosTear